Journal of Biotechnology and Biomedical Science

Dr. Eman Refaat Youness, Assistant Professor, Department Of Medical Biochemistry

ORCID: 0000-0002-6492-1680
Editorial Board

Dr. Eman Refaat Youness PhD

Assistant Professor, Department Of Medical Biochemistry ORCID: 0000-0002-6492-1680 · Egypt

Editorial leadership for Journal of Biotechnology and Biomedical Science ISSN 2576-6694

Research interests

  • Dr. Youness'S Focus Spans Multiple Facets Of Clinical
  • Molecular Biochemistry: Medical Biochemistry
  • Clinical Pathology Oxidative Stress
  • Antioxidant Activity Breast Cancer
  • Hormonal Disorders (Pcos) Acute Kidney Injury (Aki)
  • Nephrology Neuroprotective Strategies
  • Neuronal Injury

Biography


Dr. Eman Refaat Youness is an Assistant Professor of Medical Biochemistry specializing in Oxidative Stress, Antioxidant Activity, and Disease Pathogenesis. Her multidisciplinary research focuses on molecular and biochemical mechanisms underlying chronic conditions, including Breast Cancer, Kidney Injury (Alport Syndrome), Polycystic Ovarian Syndrome (PCOS), and Cerebral Ischemia. Dr. Youness employs her expertise to identify novel biomarkers (like NGAL and L-FABP) for early diagnosis and to evaluate the protective role of various therapeutic agents and antioxidants.


Education Details

Dr. Youness's foundational education is rooted in clinical and medical biochemistry from prestigious Egyptian universities:

  • M.D. (Medical Biochemistry): Faculty Of Medicine, Cairo University (2009).
  • M.Sc. (Medical Biochemistry): Faculty Of Medicine, Cairo University (1993).
     
Professional Background

Her career has been dedicated to research and education within Egypt's premier research institutions:

  • Assistant Professor (Current) - Department Of Medical Biochemistry, National Research Centre (NRC), Cairo, Egypt.
  • Member (Current) - Medical Biochemistry Unit, NRC

Current Research Projects

Her current research efforts focus on biomarker discovery and neuroprotection in various disease models:

  • Neuroprotection: Investigating the protective effect of Magnesium salts and other compounds in models of transient global cerebral ischemia and drug-induced neuronal injury.

  • Disease Biomarkers: Assessing the role of inflammatory markers (like COX-2, IL-4) in Alport Syndrome progression and the status of zinc in Sickle Cell Disease.

Academic Profiles Of Dr. Eman Refaat Youness

Explore her academic and professional presence across trusted platforms:

Selected publications

Dr. Youness's publications are highly current, detailing new findings on biochemical biomarkers, neuroprotection, and oxidative stress pathways in various clinical conditions. The list of recent publications of Dr. Eman Refaat Youness is listed below:

  • Youssry, I., El-Ghamrawy, M., Youness, E. R., et al. (2025). Zinc Level and Its Impact on the Phenotype of Sickle Cell Disease. Annals Of Hematology.
  • Abdel-Salam, O. M. E., Youness, E. R., El Baset, M. A., et al. (2025). Neuroprotective Effect of Magnesium Oxide/gluconate in Transient Global Cerebral Ischemia in the Rat Brain. International Journal Of Applied Sciences & Development.
  • Sleem, A. A., Youness, E. R., Omara, E. A., & Abdel-Salam, O. M. E. (2025). Brain Derived Neurotrophic Factor and Neuron Specific Enolase Levels As Markers of Drugs of Abuse Induced Neuronal Injury. Molecular Sciences And Applications.
  • Zaki, M., El Sherity, S. Y., Girgiss, M. W., Youness, E. R., et al. (2024). Total Antioxidant Capacity Status in Non-Obese Adolescent Females with PCOS: A Cross Section Study. Middle East Fertility Society Journal.
  • Askar, A., El-Sayed, A., Youness, E. R., et al. (2024). Helicobacter Pylori Infection and Microalbuminuria in Diabetic Patients. Biomedical And Pharmacology Journal.

 

Last Updated on September 30, 2025

Considering JBBS for your work?

This journal is guided by Dr. Eman Refaat Youness (Assistant Professor, Department Of Medical Biochemistry ORCID: 0000-0002-6492-1680) and a peer-review board of practising researchers. Open access, author-retained copyright (CC BY), and a clear editorial process.

Start your submission

Menu